Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Study Overview

This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.

The interventions involved in this study are:

  • Carboplatin
  • Nivolumab

Study Description

A randomized phase II trial of carboplatin with or without nivolumab in first-line metastatic triple-negative breast cancer

  • ClinicalTrials.gov Identifier: NCT03414684
  • Protocol Number: 17-512

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000